Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7238979 | 1.00 | CCR2 (0.60) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL20581684 | 1.00 | CCR2 (0.60) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL3487757 | 0.94 | CCR2 (0.68) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL3241217 | 0.94 | CCR2 (0.68) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL319610 | 0.94 | CCR2 (0.68) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL7238858 | 0.93 | CCR2 (0.71) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL7383773 | 0.88 | CCR2 (0.50) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL3936733 | 0.88 | CCR2 (0.50) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL14778920 | 0.88 | CCR2 (0.50) | CCR2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL4074289 | 0.83 | CCR2 (0.61) | CCR2RAB9AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-3986903-B1 | BIARYL DIALKYL PHOSPHINE OXIDE FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230046194-A1 | Ribosome-Mediated Incorporation of Peptides and Peptidomimetics | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-02-16 | — | — | US | disclosed |
| US-11530183-B2 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3414227-B1 | PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11124494-B2 | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3407716-B9 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-11008301-B2 | Piperidinone formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3634956-B1 | ARYL HETEROCYCLIC PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3634955-B1 | PIPERIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-03-31 | — | — | EP | disclosed |
| WO-2013018929-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-07 | — | — | WO | disclosed |
| CN-102596936-A | Antiviral compounds | GILEAD SCIENCES INC | 2012-07-18 | — | — | CN | disclosed |
| WO-2012006055-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2029581-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1824844-B1 | PYRAZINE DICARBOXAMIDES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007126871-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1824844-A1 | PYRAZINE DICARBOXAMIDES AND THE USE THEREOF | Bayer HealthCare AG (DE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006061116-A1 | PYRAZINE DICARBOXAMIDES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-06-15 | — | — | WO | disclosed |
| US-6297233-B1 | Lactam inhibitors of FXa and method | BRISTOL-MYERS SQUIBB COMPANY | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | CCR2 2421/4885RAB9A 656/4885ALDH1A1 1062/4885 |
| US-20230046194-A1 | Ribosome-Mediated Incorporation of Peptides and Peptidomimetics | NPEPPS, DNPEP, AARS1 | CCR2 3540/4885RAB9A 3287/4885ALDH1A1 4835/4885 |
| US-11124494-B2 | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | CCR2 21/4885RAB9A 3669/4885ALDH1A1 3593/4885 |
| US-11530183-B2 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | CCR2 13/4885RAB9A 3745/4885ALDH1A1 3799/4885 |
| US-11008301-B2 | Piperidinone formyl peptide 2 receptor agonists | FPR1, FPR2, FPR3 | CCR2 24/4885RAB9A 3396/4885ALDH1A1 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.